John J. Bissler, MD
Clark D. West Endowed Chair of Nephrology
Associate Professor
Associate Program Director for Research and Academic Careers
Education and Training
- BS, Kent State University
- MD, Northeastern Ohio University
- Pediatrics, Children's Hospital Medical Center, Akron
- Pediatric Nephrology, Children's Hospital Medical Center, Cincinnati
- William Cooper Procter Research Scholar, Cincinnati Children's Research Foundation, Cincinnati
Clinical Interests
Hemofiltration and autosomal dominant polycystic kidney disease
Research Interests
Dr. Bissler has two major research focuses. His basic science interests revolve around DNA biochemistry and the role of intrinsic DNA instability leading to disease. His work has identified several inherited diseases that have renal involvement that can be explained by alternative DNA structure mutagenesis. These structures include A-B helix transitions, cruciform extrusion and triplex DNA formation. His major focus is on DNA directed mutagenesis within the PKD1 gene. Mutations in this gene lead to autosomal dominant polycystic kidney disease.
Dr. Bissler's clinical research focus revolves around the computerization of hemodialysis and hemofiltration. Specifically, Drs. Bissler and Marios Polycarpou at the Department of Electrical and Computer Engineering, University of Cincinnati, are working with adaptive and intelligent control systems as applied to pediatric nephrology procedures. These control algorithms can both control and learn from experience smoothing procedures with easing of physician and nurse time demands.
Dr. Bissler attends the Tuberous Sclerosis Clinic in Cincinnati. This clinic has over 300 patients, making it one of the largest TS clinics in the world. Dr. Bissler cares for the renal component of this disease process. Furthermore, in conjunction with Dr. David Franz, Director of the Tuberous Sclerosis Clinic and Dr. Frank McCormack, Pulmonologist who specializes in the lymphangioleiomyomatosis, Dr. Bissler is conducting a clinical trial in hopes to discover a pharmacological treatment for the renal lesion of TS.
Dr. Bissler is also on the faculty of the Interdisciplinary Graduate Program in Cell and Molecular Biology at the University of Cincinnati.
Representative Recent Publications
- Williams JM, Racadio JM, Johnson ND, Donnelly LF, Bissler JJ. Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex. Am J Kidney Dis. 47(1):95-102, 2006.
- Zahedi K, Revelo MP, Barone S, Wang Z, Tehrani K, Citron DP, Bissler JJ, Rabb H, Soleimani M. Stathmin-deficient mice develop fibrosis and show delayed recovery from ischemic-reperfusion injury. Am J Physiol Renal Physiol. 290(6):F1559-67, 2006.
- Robison JG, Lu L, Dixon K, Bissler JJ. DNA lesion-specific co-localization of the Mre11/Rad50/Nbs1 (MRN) complex and replication protein A (RPA) to repair foci. J Biol Chem. 280:12927-12934, 2005.
- Nguyen MT, Bissler JJ. Chapter 87: Acute Renal Failure in Pediatric Critical Care Medicine: Basic Science and Clinical Evidence. Wheeler, Wong and Shanley, Editors, 2005, Springer-Verlag: London. (In Press)
- Bissler JJ, Dixon BP. A mechanistic approach to inherited polycystic kidney disease. Pediatr Nephrol. 20:558-566, 2005.
- Williams J, Donnelly L, Johnson N, Racadio J, Bissler J. Prophylactic embolization of renal angiomyolipomas in patients with tuberous sclerosis. Journal Of Reontgenology (2005, In Press).
- VanDeVoorde, R, Bissler JJ, Section XI: Nephrology and Genitourinary Tract: Chapter 9: Hematuria and Proteinuria, in Current Pediatric Therapy, Burg FD, et al., Editors. 2005, Saunders: New York.
- Cicardi M, Bissler JJ, Sullivan KE. Swelling isn't swell. Clin Immunol. 113:231-233, 2004.
- Bissler JJ, Kingswood JC. Renal angiomyolipomata. Kidney Int. 66:924-934, 2004.
- Fricke BL, Donnelly LF, Casper KA, Bissler JJ. Frequency and imaging appearance of hepatic angiomyolipomas in pediatric and adult patients with tuberous sclerosis. AJR Am J Roentgenol. 182:1027-1030, 2004.
- Patel HP, Lu L, Blaszak RT, Bissler JJ. PKD1 intron 21: triplex DNA formation and effect on replication. Nucleic Acids Res. 32:1460-1468, 2004.
- Hopkin RJ, Bissler J, Grabowski GA. Comparative evaluation of alpha-galactosidase A infusions for treatment of Fabry disease. Genet Med. 5:144-153, 2003.
- Potaman VN, Bissler JJ, Hashem VI, Oussatcheva EA, Lu L, Shlyakhtenko LS, Lyubchenko YL, Matsuura T, Ashizawa T, Leffak M, Benham CJ, Sinden RR. Unpaired structures in SCA10 (ATTCT)n.(AGAAT)n repeats. J Mol Biol. 326:1095-1111, 2003.
- Brady RC, Bissler JJ. Renal, hepatic, and marrow dysfunction in a patient with chronic renal insufficiency. Pediatr Nephrol. 18:293-296, 2003.
- Bissler JJ. Parenteral Fluid Therapy for Infants and Children. In: Rakel RE, Bope ET, eds. Conn's Current Therapy. 55th ed: W. B. Saunders Company; 2003.
- Dabora SL, Roberts P, Nieto A, Perez R, Jozwiak S, Franz D, Bissler J, Thiele EA, Sims K, Kwiatkowski DJ. Association between a high-expressing interferon-gamma allele and a lower frequency of kidney angiomyolipomas in TSC2 patients. Am J Hum Genet. 71:750-758, 2002.
- Casper KA, Donnelly LF, Chen B, Bissler JJ. Tuberous sclerosis complex: renal imaging findings. Radiology. 225:451-456, 2002.
- Lu L, Patel H, Bissler JJ. Optimizing DpnI digestion conditions to detect replicated DNA. Biotechniques. 33:316-318, 2002.
- Rosenberg ME, Girton R, Finkel D, Chmielewski D, Barrie A, 3rd, Witte DP, Zhu G, Bissler JJ, Harmony JA, Aronow BJ. Apolipoprotein J/clusterin prevents a progressive glomerulopathy of aging. Mol Cell Biol. 22:1893-1902, 2002.
- Bissler JJ, Racadio J, Donnelly LF, Johnson ND. Reduction of postembolization syndrome after ablation of renal angiomyolipoma. Am J Kidney Dis. 39:966-971, 2002.
- Bissler JJ, Tsoras M, Goring HH, Hug P, Chuck G, Tombragel E, McGraw C, Schlotman J, Ralston MA, Hug G. Infantile dilated X-linked cardiomyopathy, G4.5 mutations, altered lipids, and ultrastructural malformations of mitochondria in heart, liver, and skeletal muscle. Lab Invest. 82:335-344, 2002.
Funding
DNA Structure and Mutagenesis
- DNA Replication Fork: Pausing, Recombination and Disease
Agency: NIH (R01 DK061458)
PI: John J. Bissler, MD
Dates/Effort: 5/1/03-4/30/08 (25%)
Total Direct Costs: $1,025,002
Goal: To investigate the contribution of alternative DNA secondary structures to replication fork arrest and induction of recombination. No overlap. Utility of Rapamycin for the Treatment of Renal Angiomyolipomas
- Utility of Rapamycin for the Treatment of Renal Angiomyolipomas
Agency: NIH (R21CA103486)
PI: John J. Bissler, MD
Dates/Effort: 07/01/03-06/30/06 (30%)
Total Direct Costs: $445,000
Goal: To assess the role of rapamycin in the treatment of renal angiomyolipomas. - Utility of Rapamycin for the Treatment of Renal Angiomyolipomas
Agency: TS Alliance
PI: John Bissler, MD
Dates/Effort: 7/1/03-6/30/06 (0%)
Total costs: $100,000
Goal: To assess the role of rapamycin in the treatment of renal angiomyolipomas. - RAD001 Therapy of Angiomyolipomata in Patients with Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis
Agency: Novartis
PI: John Bissler, MD
Dates/Effort: 10/1/04-9/30/06 (30%)
Total costs: $622,248
Goal: To assess the role of everlimus in the treatment of renal angiomyolipomata. - Natural History of Tuberous Sclerosis: Renal Disease
Agency: Department of Defense
PI: John Bissler, MD
Dates: 06/01/05-05/31/08
Total costs: $1,000,000
Goal: To assess the natural history of the renal lesions in tuberous sclerosis complex.
